MabGenesis
Tokyo, Japan· Est.
A biotech startup using proprietary antibody libraries to develop species-specific therapeutics for human oncology and veterinary medicine.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
A biotech startup using proprietary antibody libraries to develop species-specific therapeutics for human oncology and veterinary medicine.
OncologyImmunology
Technology Platform
Proprietary MOURA antibody libraries (species-specific for human, canine, feline) combined with the IMPACT high-efficiency monoclonal antibody isolation technology.
Opportunities
The rapidly growing companion animal therapeutics market, projected to reach $6B by 2032, and the demand for safer, fully species-specific antibodies in both human and veterinary medicine.
Risk Factors
As an early-stage platform company, it faces risks of failing to secure validation partnerships, competition from established antibody discovery platforms, and the significant cost and complexity of dual human/veterinary development.
Competitive Landscape
Competes with large antibody discovery CROs (e.g., Abzena, Ligand's OmniAb) and animal health companies in veterinary biologics; differentiation is its claim of superior library quality and focus on 100% species-specific antibodies for pets.